Trial Information

Summary: Provigil for Fatigue

Columbia University's HIV Clinical Research Program

Who is eligible? HIV+ men and women with persistent fatigue that interferes with daily activities. Certain medical restrictions apply.

What is Provigil? This medication is approved by the FDA to treat excessive daytime sleepiness. We are investigating its use for HIV-related fatigue.

What is involved? This is a 4-week trial of Provigil. We offer an additional 2 months of Provigil or an alternate treatment depending on response. Compensation is provided for monthly assessments.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:44:46 AM